CL2023000289A1 - Combinaciones para el tratamiento de cáncer - Google Patents
Combinaciones para el tratamiento de cáncerInfo
- Publication number
- CL2023000289A1 CL2023000289A1 CL2023000289A CL2023000289A CL2023000289A1 CL 2023000289 A1 CL2023000289 A1 CL 2023000289A1 CL 2023000289 A CL2023000289 A CL 2023000289A CL 2023000289 A CL2023000289 A CL 2023000289A CL 2023000289 A1 CL2023000289 A1 CL 2023000289A1
- Authority
- CL
- Chile
- Prior art keywords
- combinations
- compound
- relates
- cancer treatment
- crystalline forms
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a combinaciones que comprenden un inhibidor de punto de control y un inhibidor de c-Met, el Compuesto 1. La invención también se refiere a formas cristalinas de la base libre del Compuesto 1, así como también formas cristalinas de sales del Compuesto 1, en combinación con un inhibidor de punto de control. La invención también se refiere una composición farmacéutica que comprende estas combinaciones. La invención además se refiere a métodos para tratar un cáncer administrando el Compuesto 1 como un agente único o una combinación descrita en este documento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063059601P | 2020-07-31 | 2020-07-31 | |
US202063113556P | 2020-11-13 | 2020-11-13 | |
US202163148921P | 2021-02-12 | 2021-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023000289A1 true CL2023000289A1 (es) | 2023-09-01 |
Family
ID=77431400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023000289A CL2023000289A1 (es) | 2020-07-31 | 2023-01-30 | Combinaciones para el tratamiento de cáncer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230301979A1 (es) |
EP (1) | EP4188376A1 (es) |
JP (1) | JP2023536264A (es) |
KR (1) | KR20230059792A (es) |
CN (1) | CN116437954A (es) |
AU (1) | AU2021318134A1 (es) |
BR (1) | BR112023001792A2 (es) |
CA (1) | CA3186517A1 (es) |
CL (1) | CL2023000289A1 (es) |
CO (1) | CO2023001561A2 (es) |
CR (1) | CR20230052A (es) |
IL (1) | IL300151A (es) |
MX (1) | MX2023001298A (es) |
PE (1) | PE20231369A1 (es) |
TW (1) | TW202220654A (es) |
WO (1) | WO2022026706A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20200358A (es) * | 2018-01-26 | 2021-02-22 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
WO2023172917A1 (en) * | 2022-03-07 | 2023-09-14 | Sanofi-Aventis U.S. Llc | Use of isatuximab in combination with other agents for the treatment of multiple myeloma |
WO2023196899A2 (en) * | 2022-04-08 | 2023-10-12 | Global Cancer Technology | Methods and products to screen and treat glioblastoma multiforme and other cancers, including breast cancers, using a combination of pi3kinase inhibitors with checkpoint inhibitors |
WO2024086563A1 (en) * | 2022-10-19 | 2024-04-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Therapeutic methods with target-linked small molecules and anti-target car t cells |
CN117285533B (zh) * | 2023-11-24 | 2024-01-30 | 四川省医学科学院·四川省人民医院 | CD47/SIRPα小分子抑制剂及其应用和抗肿瘤药物组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳-法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
CN105339389B (zh) | 2013-05-02 | 2021-04-27 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
JP2019529476A (ja) * | 2016-09-27 | 2019-10-17 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | N−(4−(6,7−ジメトキシキノリン−4−イルオキシ)フェニル)−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法 |
BR112019015011A2 (pt) * | 2017-01-20 | 2020-04-28 | Exelixis Inc | combinações de cabozantinibe e atezolizumabe para tratar câncer |
CR20200358A (es) * | 2018-01-26 | 2021-02-22 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
AU2019395419A1 (en) | 2018-12-13 | 2021-07-01 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
-
2021
- 2021-07-29 CN CN202180065378.8A patent/CN116437954A/zh active Pending
- 2021-07-29 US US18/018,805 patent/US20230301979A1/en active Pending
- 2021-07-29 CR CR20230052A patent/CR20230052A/es unknown
- 2021-07-29 AU AU2021318134A patent/AU2021318134A1/en active Pending
- 2021-07-29 CA CA3186517A patent/CA3186517A1/en active Pending
- 2021-07-29 WO PCT/US2021/043699 patent/WO2022026706A1/en active Application Filing
- 2021-07-29 MX MX2023001298A patent/MX2023001298A/es unknown
- 2021-07-29 KR KR1020237006875A patent/KR20230059792A/ko unknown
- 2021-07-29 PE PE2023000162A patent/PE20231369A1/es unknown
- 2021-07-29 IL IL300151A patent/IL300151A/en unknown
- 2021-07-29 BR BR112023001792A patent/BR112023001792A2/pt unknown
- 2021-07-29 EP EP21758525.6A patent/EP4188376A1/en active Pending
- 2021-07-29 JP JP2023506226A patent/JP2023536264A/ja active Pending
- 2021-07-30 TW TW110128221A patent/TW202220654A/zh unknown
-
2023
- 2023-01-30 CL CL2023000289A patent/CL2023000289A1/es unknown
- 2023-02-14 CO CONC2023/0001561A patent/CO2023001561A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR20230052A (es) | 2023-04-11 |
WO2022026706A1 (en) | 2022-02-03 |
TW202220654A (zh) | 2022-06-01 |
AU2021318134A1 (en) | 2023-03-02 |
CA3186517A1 (en) | 2022-02-03 |
EP4188376A1 (en) | 2023-06-07 |
PE20231369A1 (es) | 2023-09-07 |
KR20230059792A (ko) | 2023-05-03 |
CN116437954A (zh) | 2023-07-14 |
JP2023536264A (ja) | 2023-08-24 |
MX2023001298A (es) | 2023-02-22 |
IL300151A (en) | 2023-03-01 |
US20230301979A1 (en) | 2023-09-28 |
BR112023001792A2 (pt) | 2023-04-11 |
CO2023001561A2 (es) | 2023-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
ECSP21080535A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
CO2021015067A2 (es) | Compuestos antivirales que contienen nitrilo | |
CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
CR20190252A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
UY39027A (es) | Uso de favipiravir en el tratamiento de la infección por coronavirus | |
CO2021015624A2 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos | |
CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
CL2023002383A1 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
CO2022000481A2 (es) | Inhibidores de enzimas | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
AR122352A1 (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este | |
CO2022000266A2 (es) | Inhibidores de enzimas | |
CO2021004004A2 (es) | Composición tópica inyectable | |
CL2023000943A1 (es) | Formas cristalinas de un compuesto farmacéutico. | |
BR112023021913A2 (pt) | Tratamento de câncer com inibidor de raf | |
UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos | |
AR128636A1 (es) | Inhibidor de recaptación triple para el tratamiento de la depresión atípica | |
AR108792A1 (es) | Composiciones que comprenden timolol | |
ECSP16095557A (es) | Métodos para tratar infecciones | |
AR118933A1 (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres | |
AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas |